Bioventus said today it won FDA approval for its Durolane injectable product designed for joint lubrication and treating pain associated with knee osteoarthritis.
Durolane is a single-injection, hyaluornic acid product designed to lubricate joints to treat pain associated with knee osteoarthritis, Durham, N.C.-based Bioventus said. The company acquired it last December from Galderma for an undisclosed amount.
Bioventus said its Durolane product will complement its existing osteoarthritis portfolio, including its 3-injection HA Gelsyn-3 and 5-injection HA Supartz Fx. The company said it plans to launch Durolane in US markets early next year.
“More than 20 million Americans are afflicted with knee osteoarthritis and there is no cure, but the associated pain can be managed. Durolane has been a proven knee OA pain reliever for more than 15 years, improving the lives of more than one million people worldwide. It will join our current offerings to provide even more efficacious treatment options for US patients, physicians and payers,” CEO Tony Bihl said in a press release.
Last September, Bioventus said it launched the Exogen ultrasound bone healing system in Saudi Arabia.